Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with naïve rather than differentiated T cells

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2545-2552

  Ishikawa, Takeshi ^a,b   Adachi, Satoko ^b   Okayama, Tetsuya ^a,b   Kokura, Satoshi ^a,c   Mizushima, Katsura ^a   Doi, Toshifumi ^a   Matsuyama, Tatsuzo ^a   Sakamoto, Naoyuki ^a   Katada, Kazuhiro ^a   Kamada, Kazuhiro ^a   Uchiyama, Kazuhiko ^a   Handa, Osamu ^a   Takagi, Tomohisa ^a   Naito, Yuji ^a   Itoh, Yoshito ^a   Yoshikawa, Toshikazu ^b  

^a Department of Molecular Gastroenterology and Hepatology ^*  (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Kyoto University of Advanced Science   (Japan)

Author keywords

Adoptive T cell therapy; CTLA 4 antibody; Na ve T cell; T helper 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNOGLOBULIN G; L SELECTIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD3+ T LYMPHOCYTE; CELL POLARITY; CELL THERAPY; CLINICAL EFFECTIVENESS; COLON ADENOCARCINOMA; CONTROLLED STUDY; INHIBITION KINETICS; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROCEDURES; REGULATORY T LYMPHOCYTE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL- AND TISSUE-BASED THERAPY; CTLA-4 ANTIGEN; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84927145706     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3815     Document Type: Article

References (39)

1. Krummel MF and Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540, 1996.
2. Alegre ML, Frauwirth KA and Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220-228, 2001.
3. + T cells. Immunity 7:885-895, 1997.
4. Greenwald RJ, Oosterwegel MA, Van Der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA and Sharpe AH: CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366-373, 2002.
5. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H and Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988, 1995.
6. Ribas A, Kefford R, Marshall MA, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616-622, 2013.
7. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010.
8. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011.
9. Grosso JF and Jure-Kunkel MN: CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun 13:5, 2013.
10. Mokyr MB, Kalinichenko T, Gorelik L and Bluestone JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 58:5301-5304, 1998.
11. Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC and Demaria S: Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res 15:597-606, 2009.
12. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP and Formenti SC: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728-734, 2005.
13. Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L and Allison JP: Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72:430-439, 2012.
14. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM and Burg MB: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 96:15074-15079, 1999.
15. Hurwitz AA, Yu TF, Leach DR and Allison JP: CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colonystimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95:10067-10071, 1998.
16. Pedersen AE, Buus S and Claesson MH: Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett 235:229-238, 2006.
17. Met O, Wang M, Pedersen AE, Nissen MH, Buus S and Claesson MH: The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 231:247-256, 2006.
18. Davila E, Kennedy R and Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63:3281-3288, 2003.
19. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ and Ellenhorn JD: Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 64:5407-5414, 2004.
20. Kocak E, Lute K, Chang X, et al: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 66:7276-7284, 2006.
21. Curran MA, Montalvo W, Yagita H and Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275-4280, 2010.
22. + T cells. J Clin Invest 115:1616-1626, 2005.
23. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA and Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28:258-267, 2005.
24. Watanabe A, Hara M, Chosa E, Nakamura K, Sekiya R, Shimizu T and Onitsuka T: Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice - an in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb-. Immunopharmacol Immunotoxicol 32:238-245, 2010.
25. Simpson TR, Li F, Montalvo-Ortiz W, et al: Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695-1710, 2013.
26. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M and Korman AJ: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32-42, 2013.
27. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310, 2000.
28. Curran MA and Allison JP: Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69:7747-7755, 2009.
29. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105:14987-14992, 2008.
30. Hodi FS, Butler M, Oble DA, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005-3010, 2008.
31. Bluestone JA and Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253-257, 2003.
32. + regulatory T cells. Immunology 109:319-325, 2003.
33. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198:1875-1886, 2003.
34. + T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 33:386-390, 2006.
35. Van Elsas A, Hurwitz AA and Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999.
36. Perrin PJ, Maldonado JH, Davis TA, June CH and Racke MK: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 157:1333-1336, 1996.
37. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD and Bluestone JA: CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184:783-788, 1996.
38. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999.
39. Ishikawa T, Kokura S, Enoki T, et al: Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. PLoS One 9:e83786, 2014.